New gene therapy trial aims to control hepatitis b virus
NCT ID NCT07200193
First seen Nov 01, 2025 · Last updated Apr 16, 2026 · Updated 23 times
Summary
This early-stage study is testing a new gene therapy called CRMA-1001 in adults with chronic hepatitis B. The main goal is to check if the treatment is safe and how the body processes it, while also looking for early signs it might help control the virus. Participants will receive the therapy through an IV infusion and will continue taking their standard antiviral medications during the study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPAITITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New Zealand Clinical Research
RECRUITINGAuckland, New Zealand
Contact
-
Queen Mary Hospital, The University of Hong Kong
RECRUITINGHong Kong, 999077, Hong Kong
Contact
Conditions
Explore the condition pages connected to this study.